Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

• Main Authors: M. Karolyi (Author), E. Pawelka (Author), S. Omid (Author), F. Koenig (Author), V. Kauer (Author), B. Rumpf (Author), W. Hoepler (Author), A. Kuran (Author), H. Laferl (Author), T. Seitz (Author), M. Traugott (Author), V. Rathkolb (Author), M. Mueller (Author), A. Abrahamowicz (Author), C. Schoergenhofer (Author), M. Hecking (Author), A. Assinger (Author), C. Wenisch (Author), M. Zeitlinger (Author), B. Jilma (Author), A. Zoufaly (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: To date, no oral antiviral drug has proven to be beneficial in hospitalized patients with COVID-19.Methods: In this randomized, controlled, open-label, platform trial, we randomly assigned patients ≥18 years hospitalized with COVID-19 pneumonia to receive either camostat mesylate (CM) (c...